发布时间：2025-09-08 15:07 – Takeda is the Leader in Orexin Science and is on Track to Submit Global Regulatory Applications Starting in Fiscal Year 2025

– Four Orexin Oral Presentations from Phase 3 Pivotal Studies Highlight Statistically Significant and Clinically Meaningful Improvement in Narcolepsy Type 1 Symptoms Demonstrating the Potential for a New Era of Care

– Oveporexton was Generally Well-Tolerated with Safety Profile Consistent with Previous Clinical Studies
SINGAPORE & OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK)will present data from two global Phase 3 double-blind, placebo-controlled studies of oveporexton (TAK-861)1, a potential first-in-class investigational oral orexin receptor 2 (OX2R)-selective agonist in narcolepsy type 1 (NT1), during multiple oral presentations at the World Sleep 2025 Congress in Singapore beginning at 3:15 p.m. SGT today.




Both the FirstLight (TAK-861-3001) and RadiantLight (TAK-8
=*=*=*=*=*=
当前为第1/18页
下一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页